Evaluating dynamic contrast-enhanced MRI for differentiating HER2-zero, HER2-low, and HER2-positive breast cancers in patients undergoing neoadjuvant chemotherapy.

Objectives: To quantitatively assess the differences in parameters of dynamic contrast-enhanced MRI (DCE-MRI) in HER2-zero, HER2-low, or HER2-positive tumors, and to build optimal model for early prediction of HER2-low breast cancer (BC).

Materials And Methods: Clinical and DCE-MRI data from 220 BC patients receiving neoadjuvant chemotherapy (NACT) were retrospectively analyzed. Quantitative and semi-quantitative DCE-MRI parameters were compared in the HER2-zero, HER2-low, or HER2-positive groups before and after early NACT.